Arnaud Jaccard

14.7k total citations · 1 hit paper
205 papers, 6.1k citations indexed

About

Arnaud Jaccard is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Arnaud Jaccard has authored 205 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 104 papers in Molecular Biology, 56 papers in Genetics and 55 papers in Oncology. Recurrent topics in Arnaud Jaccard's work include Amyloidosis: Diagnosis, Treatment, Outcomes (96 papers), Multiple Myeloma Research and Treatments (40 papers) and Chronic Lymphocytic Leukemia Research (35 papers). Arnaud Jaccard is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (96 papers), Multiple Myeloma Research and Treatments (40 papers) and Chronic Lymphocytic Leukemia Research (35 papers). Arnaud Jaccard collaborates with scholars based in France, United States and Italy. Arnaud Jaccard's co-authors include Frank Bridoux, Giampaolo Merlini, Jean‐Paul Fermand, Giovanni Palladini, Angela Dispenzieri, Dominique Bordessoule, Bruno Royer, Ashutosh Wechalekar, Raymond L. Comenzo and Stefan Schönland and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Arnaud Jaccard

189 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes

2012 625 citations Giovanni Palladini, Angela Dispenzieri et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arnaud Jaccard France	39	3.3k	1.8k	1.6k	1.4k	1.2k	205	6.1k
Véronique Leblond France	43	1.8k 0.5×	2.5k 1.4×	3.1k 2.0×	2.1k 1.6×	3.1k 2.7×	218	7.2k
Bertrand Arnulf France	37	2.4k 0.7×	1.6k 0.9×	763 0.5×	2.3k 1.7×	457 0.4×	167	4.8k
Jean‐Claude Brouet France	33	1.3k 0.4×	887 0.5×	1.2k 0.8×	1.3k 1.0×	1.0k 0.9×	81	5.3k
Joseph A. DiGiuseppe United States	31	1.2k 0.4×	1.5k 0.8×	515 0.3×	554 0.4×	1.0k 0.9×	69	4.9k
Rudolf A. Manz Germany	36	1.1k 0.3×	805 0.4×	525 0.3×	791 0.6×	568 0.5×	77	6.0k
William G. Morice United States	34	845 0.3×	991 0.6×	1.2k 0.8×	850 0.6×	1.3k 1.1×	90	3.4k
Fiona E. Craig United States	29	508 0.2×	1.4k 0.8×	736 0.5×	801 0.6×	1.4k 1.2×	104	4.0k
Junji Suzumiya Japan	45	920 0.3×	3.6k 2.0×	908 0.6×	684 0.5×	4.0k 3.5×	227	7.2k
Martin Gramatzki Germany	46	2.1k 0.6×	2.5k 1.4×	844 0.5×	1.8k 1.3×	1.2k 1.0×	207	6.8k
Scott A. Rollins United States	38	1.1k 0.3×	244 0.1×	1.3k 0.8×	1.9k 1.4×	372 0.3×	63	7.2k

Countries citing papers authored by Arnaud Jaccard

Since Specialization

Citations

This map shows the geographic impact of Arnaud Jaccard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnaud Jaccard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnaud Jaccard more than expected).

Fields of papers citing papers by Arnaud Jaccard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnaud Jaccard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnaud Jaccard. The network helps show where Arnaud Jaccard may publish in the future.

Co-authorship network of co-authors of Arnaud Jaccard

This figure shows the co-authorship network connecting the top 25 collaborators of Arnaud Jaccard. A scholar is included among the top collaborators of Arnaud Jaccard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnaud Jaccard. Arnaud Jaccard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pagès, Arnaud, Rudy Birsen, Adrien Contejean, et al.. (2024). Venetoclax–proteasome inhibitor–dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm. Blood Advances. 9(4). 793–796. 2 indexed citations

Hulin, Cyrille, Jérôme Lambert, Salomon Manier, et al.. (2024). Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).. Journal of Clinical Oncology. 42(16_suppl). 7501–7501. 1 indexed citations

Bridoux, Frank, Nelson Leung, Samih H. Nasr, Arnaud Jaccard, & Virginie Royal. (2024). Kidney disease in multiple myeloma. La Presse Médicale. 54(1). 104264–104264. 1 indexed citations

Kastritis, Efstathios, Giovanni Palladini, Meletios Α. Dimopoulos, et al.. (2024). Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network. Blood. 144(Supplement 1). 1927–1927.

Wechalekar, Ashutosh, María Teresa Cibeira, Simon Gibbs, et al.. (2022). Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 30(1). 3–17. 46 indexed citations

Minnema, Monique C., Angela Dispenzieri, Giampaolo Merlini, et al.. (2022). Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis. JACC CardioOncology. 4(4). 474–487. 12 indexed citations

Moreau, Stéphane, et al.. (2022). Development of a decision tree for the pharmacy-led consultation of elderly patients with haematological malignancies. Journal of Oncology Pharmacy Practice. 29(3). 685–694.

Lentzsch, Suzanne, Samuel Pan, Divaya Bhutani, et al.. (2021). Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer Journal. 11(1). 10–10. 70 indexed citations

Bender, Sébastien, Vincent Javaugue, Alexis Saintamand, et al.. (2020). Immunoglobulin variable domain high-throughput sequencing reveals specific novel mutational patterns in POEMS syndrome. Blood. 135(20). 1750–1758. 27 indexed citations

10.

Wechalekar, Ashutosh, Giovanni Palladini, Giampaolo Merlini, et al.. (2020). Rapid and Deep Hematologic Responses Are Associated with Improved Major Organ Deterioration Progression-Free Survival in Newly Diagnosed AL Amyloidosis: Results from Andromeda. Blood. 136(Supplement 1). 6–7. 5 indexed citations

11.

Camus, Vincent, Sydney Dubois, Pierre‐Alain Thiébaut, et al.. (2019). Light chain lambda myeloma with fatal AL cardiac amyloidosis in a 21‐year‐old patient: A case report and review. SHILAP Revista de lepidopterología. 7(6). 1171–1177. 1 indexed citations

12.

Sanchorawala, Vaishali, Giovanni Palladini, Vishal Kukreti, et al.. (2017). A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 130(5). 597–605. 101 indexed citations

13.

Bras, Fabien Le, Valérie Molinier‐Frenkel, Aziz Guellich, et al.. (2017). Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis. European Journal of Cancer. 76. 183–187. 15 indexed citations

14.

Schmitz, Norbert, Maike Nickelsen, Bettina Altmann, et al.. (2015). Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial.. Journal of Clinical Oncology. 18 indexed citations

15.

Abraham, Julie, Éstelle Desport, Benôıt Marin, et al.. (2015). Hepatocyte growth factor measurement in AL amyloidosis. Amyloid. 22(2). 112–116. 8 indexed citations

16.

Cohen, Camille, Bruno Royer, Vincent Javaugue, et al.. (2015). Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney International. 88(5). 1135–1143. 79 indexed citations

17.

Moreau, Philippe, Arnaud Jaccard, Lotfi Benboubker, et al.. (2010). Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood. 116(23). 4777–4782. 96 indexed citations

18.

Trappe, Ralf Ulrich, Sylvain Choquet, Stephan Oertel, et al.. (2007). Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study. Queensland's institutional digital repository (The University of Queensland). 1 indexed citations

19.

Petit, Barbara, Christophe Le Clorennec, Arnaud Jaccard, et al.. (2005). Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup.. PubMed. 90(2). 200–6. 33 indexed citations

20.

Lortholary, Olivier, Vincent Molinié, Arnaud Jaccard, et al.. (1990). Bladder Neuropathy and Gastric Paralysis in Polyarteritis Nodosa Associated with Hepatitis B Virus. Scandinavian Journal of Rheumatology. 19(6). 442–443. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact